上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
APY29 纯度: 99.90%
APY29 是 ATP 竞争性抑制剂,一种特异性的 IRE1α 别构调节剂,通过结合到 ATP 结合口袋来抑制 IRE1α 的自主磷酸化,IC50 值为 280 nM。APY29 也可以变构激活 IRE1α 相邻 RNase 域。
APY29 Chemical Structure
CAS No. : 1216665-49-4
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥1535 | In-stock | |
10 mg | ¥1395 | In-stock | |
50 mg | ¥6045 | In-stock | |
100 mg | 询价 | ||
200 mg | 询价 |
* Please select Quantity before adding items.
APY29 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Cell Cycle/DNA Damage Compound Library
- Kinase Inhibitor Library
- Anti-Cancer Compound Library
- Anti-Aging Compound Library
- Endoplasmic Reticulum Stress Compound Library
生物活性 |
APY29, an ATP-competitive inhibitor, is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation by binding to the ATP-binding pocket with IC50 of 280 nM. APY29 acts as a ligand that allosterically activates IRE1α adjacent RNase domain[1]. |
IC50 & Target |
IC50: 280 nM (IRE1α) |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
APY29 divergently modulates the RNase activity and oligomerization state of IRE1α. APY29 is exerting their opposing effects on RNase activity through the same binding site. APY29 divergently affects IRE1α oligomerization. APY29 demonstrates opposing dose-dependent effects on ER stress-induced activation of the RNase of endogenous IRE1α[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
332.36 |
||||||||||||||||
Formula |
C17H16N8 |
||||||||||||||||
CAS 号 |
1216665-49-4 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 53.33 mg/mL (160.46 mM; Need ultrasonic) H2O : 5 mg/mL (15.04 mM; ultrasonic and adjust pH to 3 with HCl) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务